NCIt definition : An orally available, small molecule antagonist of the tyrosine kinase transforming
growth factor-beta (TGF-b) receptor type 1 (TGFBR1), with potential antineoplastic
activity. Upon administration, galunisertib specifically targets and binds to the
kinase domain of TGFBR1, thereby preventing the activation of TGF-b-mediated signaling
pathways. This may inhibit the proliferation of TGF-b-overexpressing tumor cells.
Dysregulation of the TGF-b signaling pathway is seen in a number of cancers and is
associated with increased cancer cell proliferation, migration, invasion and tumor
progression.;
UNII : 3OKH1W5LZE;
InChIKey : IVRXNBXKWIJUQB-UHFFFAOYSA-N;
CAS number : 700874-72-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 700874-72-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;